# Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

> **NCT04802161** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemia With Multilineage Dysplasia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT04802161
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-24
- **Primary completion:** 2024-11-21
- **Final completion:** 2026-04-25
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802161, "Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04802161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*